<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Serine 70 in the loop region of Bcl-2 is specifically phosphorylated by paclitaxel-treatment in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells and BHK cells expressing Bcl-2 </plain></SENT>
<SENT sid="1" pm="."><plain>The phosphorylation of serine 70 of Bcl-2 (pS70-Bcl-2) peaks 24 to 48 h after paclitaxel treatment and accelerates <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Phosphorylation is effectively inhibited in the presence of <z:chebi fb="0" ids="27666">actinomycin D</z:chebi> or <z:chebi fb="0" ids="27641">cycloheximide</z:chebi>, which restore cell viability to the same level as control cells not expressing Bcl-2 </plain></SENT>
<SENT sid="3" pm="."><plain>These results indicate that paclitaxel-induced kinase(s) and/or its activator(s) are synthesized de novo and play an important role in paclitaxel-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> by phosphorylating Bcl-2 </plain></SENT>
<SENT sid="4" pm="."><plain>In binding assays using the phosphorylation-specific antibody against pS70-Bcl-2, the induction of serine 70 phosphorylation 70 results in a loss of the binding ability of Bcl-2 to Bax, a pro-apoptotic partner, and induces subsequent cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>When the pS70-Bcl-2 antibody was added to human <z:hpo ids='HP_0003002'>breast cancer</z:hpo> tissue, serine 70 phosphorylation was also detected, even prior to treatment with anticancer agents </plain></SENT>
<SENT sid="6" pm="."><plain>Further study of <z:hpo ids='HP_0003002'>breast cancers</z:hpo> revealed 83% of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with high pS70-Bcl-2 expression responded to paclitaxel or docetaxel treatment, whereas 57% of those with low expression not respond </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest that pS70-Bcl-2 might be a predictive factor for prognosis and sensitivity to paclitaxel treatment for <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
</text></document>